Abbott injectables
Executive Summary
Abbott licenses rights to Weston Medical's needle-free technology Intraject for up to 11 therapeutic targets over 10 years. Weston said the technology is particularly well suited for delivery of monoclonal antibodies. Abbott has three monoclonal antibodies in development, including the Phase III rheumatoid arthritis therapy D2E7 (adalimumab)